<p>Exploratory transcriptomics and <em>in vivo</em> analyses of suramin in tongue squamous cell carcinoma</p>

Kakuguchi,Wataru; Morimoto,Masahiro; Takahashi,Kenta; Maishi,Nako; Hida,Kyoko; Nomura,Takao; Otsuguro,Satoko; Maenaka,Katsumi; Ohiro,Yoichi

doi:10.3892/br.2026.2112

March-2026 Volume 24 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2026 Volume 24 Issue 3

Full Size Image

Article Open Access

Exploratory transcriptomics and in vivo analyses of suramin in tongue squamous cell carcinoma

Authors:
- Wataru Kakuguchi
- Masahiro Morimoto
- Kenta Takahashi
- Nako Maishi
- Kyoko Hida
- Takao Nomura
- Satoko Otsuguro
- Katsumi Maenaka
- Yoichi Ohiro
View Affiliations / Copyright

Affiliations: Department of Oral and Maxillofacial Surgery, Division of Oral Pathobiological Science, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University, Sapporo, Hokkaido 060‑8586, Japan, Division of Head and Neck, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135‑8550, Japan, Department of Vascular Biology and Molecular Pathology, Division of Oral Pathobiological Science, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University, Sapporo, Hokkaido 060‑8586, Japan, Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060‑0812, Japan

Copyright: © Kakuguchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 39
|
Published online on: January 23, 2026

https://doi.org/10.3892/br.2026.2112
Expand metrics +

Abstract

Suramin, an anti‑trypanosomal agent, has gained attention for its potential anticancer activity, partly through the modulation of RNA‑binding proteins such as HuR. However, its genome‑wide transcriptomic effects in oral squamous cell carcinoma remain unclear. In the present study, RNA‑sequencing was performed on suramin‑treated HSC‑3 cells, followed by enrichment, network and transcription factor analyses. In vivo validation was conducted in an orthotopic xenograft model using luciferase‑labeled HSC‑3 cells. Suramin was administered intraperitoneally at a dose of 20 mg/kg, twice weekly. Transcriptomic profiling revealed broad downregulation of genes governing cell cycle progression, chromatin organization and DNA damage response, including mitotic regulators such as G₂/M regulators CCNB1, CDC20 and AURKA, and their upstream transcription factors FOXM1 and MYBL2. By contrast, genes associated with extracellular matrix remodeling (the MMP family and TIMP3) and stress or immune responses (TXNIP and TNFSF10) were upregulated. Functional enrichment confirmed the suppression of proliferative programs with the concurrent activation of tumor‑suppressive microenvironmental responses. In vivo, suramin‑treated mice exhibited lower tumor growth compared with that in the control group, although the difference was not statistically significant (P=0.18). Effect size estimates were relatively large for both the group effect (partial η²=0.20) and the time x group interaction (partial η²=0.24), suggesting that the study may have been underpowered to detect this difference statistically. In conclusion, the present exploratory study suggests that suramin exerts a dual antitumor effect on tongue squamous cell carcinoma by suppressing proliferative transcriptional programs, and modulating extracellular and stress response pathways, providing a basis for future studies to further elucidate its therapeutic relevance.

View Figures

View References

1	Coropciuc R, Moreno-Rabié C, De Vos W, Van de Casteele E, Marks L, Lenaerts V, Coppejans E, Lenssen O, Coopman R, Walschap J, et al: Navigating the complexities and controversies of medication-related osteonecrosis of the jaw (MRONJ): A critical update and consensus statement. Acta Chir Belg. 124:1–11. 2024.PubMed/NCBI View Article : Google Scholar
2	National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2026. NCCN, Plymouth Meeting, PA, 2026. https://www.nccn.org. Accessed January 8, 2026.
3	Steverding D and Troeberg L: 100 years since the publication of the suramin formula. Parasitol Res. 123(11)2023.PubMed/NCBI View Article : Google Scholar
4	Wiedemar N, Hauser DA and Mäser P: 100 years of suramin. Antimicrob Agents Chemother. 64:e01168–19. 2020.PubMed/NCBI View Article : Google Scholar
5	Zaragoza-Huesca D, Rodenas MC, Peñas-Martínez J, Pardo-Sánchez I, Peña-García J, Espín S, Ricote G, Nieto A, García-Molina F, Vicente V, et al: Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin. Biomed Pharmacother. 168(115814)2023.PubMed/NCBI View Article : Google Scholar
6	Naviaux RK, Curtis B, Li K, Naviaux JC, Bright AT, Reiner GE, Westerfield M, Goh S, Alaynick WA, Wang L, et al: Low-dose suramin in autism spectrum disorder: A small, phase I/II, randomized clinical trial. Ann Clin Transl Neurol. 4:491–505. 2017.PubMed/NCBI View Article : Google Scholar
7	Kakuguchi W, Nomura T, Kitamura T, Otsuguro S, Matsushita K, Sakaitani M, Maenaka K and Tei K: Suramin, screened from an approved drug library, inhibits HuR functions and attenuates malignant phenotype of oral cancer cells. Cancer Med. 7:6269–6280. 2018.PubMed/NCBI View Article : Google Scholar
8	Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ and Eisenberger M: Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 18:1440–1450. 2000.PubMed/NCBI View Article : Google Scholar
9	Cheng B, Gao F, Maissy E and Xu P: Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles. Acta Biomater. 84:378–390. 2019.PubMed/NCBI View Article : Google Scholar
10	Wang L, Feng Z, Wang X and Zhang X: DEGseq: An R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics. 26:136–138. 2010.PubMed/NCBI View Article : Google Scholar
11	Young TR, Yamamoto M, Kikuchi SS, Yoshida AC, Abe T, Inoue K, Johansen JP, Benucci A, Yoshimura Y and Shimogori T: Thalamocortical control of cell-type specificity drives circuits for processing whisker-related information in mouse barrel cortex. Nat Commun. 14(6077)2023.PubMed/NCBI View Article : Google Scholar
12	Foekens JA, Sieuwerts AM, Stuurman-Smeets EM, Peters HA and Klijn JG: Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro. Br J Cancer. 67:232–236. 1993.PubMed/NCBI View Article : Google Scholar
13	Al-Kharashi LA, Al-Mohanna FH, Tulbah A and Aboussekhra A: The DNA methyl-transferase protein DNMT1 enhances tumor-promoting properties of breast stromal fibroblasts. Oncotarget. 9:2329–2343. 2017.PubMed/NCBI View Article : Google Scholar
14	Zhang J, Wu Q, Xie Y, Li F, Wei H, Jiang Y, Qiao Y, Li Y, Sun Y, Huang H, et al: Ribonucleotide reductase small subunit M2 promotes the proliferation of esophageal squamous cell carcinoma cells carcinoma cells via HuR-mediated mRNA stabilization. Acta Pharm Sin B. 14:4329–4344. 2024.PubMed/NCBI View Article : Google Scholar
15	Wang J, Zhao L, Li Y, Feng S and Lv G: HuR induces inflammatory responses in HUVECs and murine sepsis via binding to HMGB1. Mol Med Rep. 17:1049–1056. 2018.PubMed/NCBI View Article : Google Scholar
16	Stetler-Stevenson WG: The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev. 27:57–66. 2008.PubMed/NCBI View Article : Google Scholar
17	Brew K and Nagase H: The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochim Biophys Acta. 1803:55–71. 2010.PubMed/NCBI View Article : Google Scholar
18	Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, Martinez-Avila N and Martinez-Fierro ML: The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 21(9739)2020.PubMed/NCBI View Article : Google Scholar
19	Escalona RM, Kannourakis G, Findlay JK and Ahmed N: Expression of TIMPs and MMPs in ovarian tumors, ascites, ascites-derived cells, and cancer cell lines: Characteristic modulatory response before and after chemotherapy treatment. Front Oncol. 11(796588)2022.PubMed/NCBI View Article : Google Scholar
20	Guns LA, Monteagudo S, Kvasnytsia M, Kerckhofs G, Vandooren J, Opdenakker G, Lories RJ and Cailotto F: Suramin increases cartilage proteoglycan accumulation in vitro and protects against joint damage triggered by papain injection in mouse knees in vivo. RMD Open. 3(e000604)2017.PubMed/NCBI View Article : Google Scholar
21	Chanalaris A, Doherty C, Marsden BD, Bambridge G, Wren SP, Nagase H and Troeberg L: Suramin inhibits osteoarthritic cartilage degradation by increasing extracellular levels of chondroprotective tissue inhibitor of metalloproteinases 3. Mol Pharmacol. 92:459–468. 2017.PubMed/NCBI View Article : Google Scholar
22	Deng J, Pan T, Liu Z, McCarthy C, Vicencio JM, Cao L, Alfano G, Suwaidan AA, Yin M, Beatson R and Ng T: The role of TXNIP in cancer: A fine balance between redox, metabolic, and immunological tumor control. Br J Cancer. 129:1877–1892. 2023.PubMed/NCBI View Article : Google Scholar
23	Ling XB, Wei HW, Wang J, Kong YQ, Wu YY, Guo JL, Li TF and Li JK: Mammalian metallothionein-2a and oxidative stress. Int J Mol Sci. 17(1483)2016.PubMed/NCBI View Article : Google Scholar
24	Si M and Lang J: The roles of metallothioneins in carcinogenesis. J Hematol Oncol. 11(107)2018.PubMed/NCBI View Article : Google Scholar
25	Liu Q, Lu F and Chen Z: Identification of MT1E as a novel tumor suppressor in hepatocellular carcinoma. Pathol Res Pract. 216(153213)2020.PubMed/NCBI View Article : Google Scholar
26	Niroshika KKH, Weerakoon K, Molagoda IMN, Samarakoon KW, Weerakoon HT and Jayasooriya RGPT: Exploring the dynamic role of circulating soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as a diagnostic and prognostic marker; a review. Biochem Biophys Res Commun. 751(151415)2025.PubMed/NCBI View Article : Google Scholar
27	Deng Y, Li AM, Zhao XM, Song ZJ and Liu SD: Downregulation of tumor protein 53-inducible nuclear protein 1 expression in hepatocellular carcinoma correlates with poor prognosis. Oncol Lett. 13:1228–1234. 2017.PubMed/NCBI View Article : Google Scholar
28	He X, Zhu Z, Johnson C, Stoops J, Eaker AE, Bowen W and DeFrances MC: PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma. Cancer Res. 68:5591–5598. 2008.PubMed/NCBI View Article : Google Scholar
29	Uche UU, Piccirillo AR, Kataoka S, Grebinoski SJ, D'Cruz LM and Kane LP: PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt. J Exp Med. 215:3165–3179. 2018.PubMed/NCBI View Article : Google Scholar
30	Peterson EJ, Woods ML, Dmowski SA, Derimanov G, Jordan MS, Wu JN, Myung PS, Liu QH, Pribila JT, Freedman BD, et al: Coupling of the TCR to integrin activation by Slap-130/Fyb. Science. 293:2263–2265. 2001.PubMed/NCBI View Article : Google Scholar
31	Chuang HY, Lee E, Liu YT, Lee D and Ideker T: Network-based classification of breast cancer metastasis. Mol Syst Biol. 3(140)2007.PubMed/NCBI View Article : Google Scholar
32	Sadasivam S and DeCaprio JA: The DREAM complex: Master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer. 13:585–595. 2013.PubMed/NCBI View Article : Google Scholar
33	Krautkramer KA, Linnemann AK, Fontaine DA, Whillock AL, Harris TW, Schleis GJ, Truchan NA, Marty-Santos L, Lavine JA, Cleaver O, et al: Tcf19 is a novel islet factor necessary for proliferation and survival in the INS-1 β-cell line. Am J Physiol Endocrinol Metab. 305:E600–E610. 2013.PubMed/NCBI View Article : Google Scholar
34	Tian Y, Xin S, Wan Z, Dong H, Liu L, Fan Z, Li T, Peng F, Xiong Y and Han Y: TCF19 promotes cell proliferation and tumor formation in lung cancer by activating the Raf/MEK/ERK signaling pathway. Transl Oncol. 45(101978)2024.PubMed/NCBI View Article : Google Scholar
35	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002.PubMed/NCBI View Article : Google Scholar
36	Walz TM, Abdiu A, Wingren S, Smeds S, Larsson SE and Wasteson A: Suramin inhibits growth of human osteosarcoma xenografts in nude mice. Cancer Res. 51:3585–3589. 1991.PubMed/NCBI
37	Zhang Y, Song S, Yang F, Au JL and Wientjes MG: Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther. 299:426–433. 2001.PubMed/NCBI
38	Kikuchi Y, Hirata J, Hisano A, Tode T, Kita T and Nagata I: Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II). Gynecol Oncol. 58:11–15. 1995.PubMed/NCBI View Article : Google Scholar
39	Church D, Zhang Y, Rago R and Wilding G: Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice. Cancer Chemother Pharmacol. 43:198–204. 1999.PubMed/NCBI View Article : Google Scholar
40	Nair AB and Jacob S: A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 7:27–31. 2016.PubMed/NCBI View Article : Google Scholar
41	Reynolds AR: Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response. 8:253–284. 2010.PubMed/NCBI View Article : Google Scholar
42	Chen D, Song SH, Wientjes MG, Yeh TK, Zhao L, Villalona-Calero M, Otterson GA, Jensen R, Grever M, Murgo AJ and Au JL: Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. Pharm Res. 23:1265–1274. 2006.PubMed/NCBI View Article : Google Scholar
43	Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW and Cornblath DR: A prospective study of suramin-induced peripheral neuropathy. Brain. 119 (Pt 6):2039–2052. 1996.PubMed/NCBI View Article : Google Scholar
44	Wu G, Zhou H, Lv D, Zheng R, Wu L, Yu S, Kai J, Xu N, Gu L, Hong N and Shentu J: Phase I, single-dose study to assess the pharmacokinetics and safety of suramin in healthy Chinese volunteers. Drug Des Devel Ther. 17:2051–2061. 2023.PubMed/NCBI View Article : Google Scholar
45	Alyoussef A: Suramin attenuated inflammation and reversed skin tissue damage in experimentally induced atopic dermatitis in mice. Inflamm Allergy Drug Targets. 13:406–410. 2015.PubMed/NCBI View Article : Google Scholar